ClinicalTrials.Veeva

Menu
P

Pacific Clinical Research Network - Tasman | Pacific Clinical Research Network - Tasman

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Molnupiravir
Retatrutide
ABI-5366
MK-0616

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials
Locations recently updated

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir

This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy part...

Enrolling
Recurrent Genital Herpes Simplex Type 2
Drug: ABI-5366
Drug: ABI-5366 Placebo

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Active, not recruiting
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Merck Sharp & Dohme (MSD) logo
A
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems